1,721,625 research outputs found
Why chemo-free treatment intervals can improve care of patients with metastatic colorectal cancer
No full text
HER2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer.
No full text
Optimizing Anti-EGFR Therapy in Colorectal Cancer
No full textTreatment with anti-EGFR monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. The major challenge is the identification of patients who would benefit from treatment. Currently, the best predictor of efficacy is the absence of mutations in KRAS and NRAS genes. Clin Cancer Res; 21(24); 5415-6. ©2015 AACR.See related article by Peeters et al., p. 5469
Editorial: the role of epidermal growth factor receptor (EGFR) targeting drugs in the treatmnet of cancer
No full text
- …
